Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
Glaukos (GKOS) Stock Price & Analysis
298 Followers
GKOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$59.22 - $126.96
Previous Close$125.28
Volume563.94K
Average Volume (3M)502.04K
Market Cap
$6.18B
Enterprise Value$6.27B
Total Cash (Recent Filing)$295.43M
Total Debt (Recent Filing)$383.74M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Jul 31, 2024EPS Estimate
-$0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding50,367,507
10 Day Avg. Volume466,373
30 Day Avg. Volume502,040
Standard Deviation0.14
R-Squared0.17
Alpha0.00645
Financial Highlights & Ratios
Price to Book (P/B)50.52
Price to Sales (P/S)69.11
Price to Cash Flow (P/CF)-133.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue19.93
Enterprise Value/Gross Profit26.23
Enterprise Value/Ebitda-76.37
Forecast
1Y Price Target
$121.09Price Target Upside-1.23% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Glaukos News
PremiumCompany Announcements
Glaukos Governance and Compensation Strategy Evolves
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommends upgrading GKOS shares to Buy from Hold following positive survey results showing strong expectations for iDose.
EarningsThe company raised the FY sales guide to $357-$365mn, indicating strong growth expectations.
Product AdoptionManagement said physician enthusiasm for iDose remains very high and noted reimbursement milestones including J-code, publication of J-Code ASP, and pro fees.
Bears Say
Gross MarginThe initial launch phase of iDose may come at a cost, with an initial hit on gross margin and higher launch costs.
Product LaunchThe company remains Neutral ahead of further updates on iDose launch progress and key reimbursement decisions.
RevenueCorneal Health revenue came in slightly below estimate driven by the impact of the Medicaid Drug Rebate Program.
---
Ownership Overview
11.21% Insiders
47.49% Mutual Funds
26.48% Other Institutional Investors
14.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $59.22 and its highest was $126.96 in the past 12 months.
What is Glaukos’s market cap?
Currently, no data Available
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Jul 31, 2024 which is in 7 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on May 01, 2024. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.577 by -$0.123.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Overvalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -$0.52.
How many shares outstanding does Glaukos have?
Glaukos has 50,367,508 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.577. Following the earnings report the stock price went up 6.187%.
Which hedge fund is a major shareholder of Glaukos?
Among the largest hedge funds holding Glaukos’s share is PRIMECAP Management Co. It holds Glaukos’s shares valued at 80M.
---
Glaukos Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$121.09 (-1.23% Downside)
$121.09 (-1.23% Downside)
Blogger Sentiment
Bullish
GKOS Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 579.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $560.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.35%
12-Months-Change
Fundamentals
Return on Equity
-29.37%
Trailing 12-Months
Asset Growth
-4.04%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
---
GKOS Earnings Call
Q1 2024
0:00 / 0:00
---
GKOS Stock 12 Month Forecast
Average Price Target
$121.09
▼(-1.23% Downside)
Technical Analysis
Best Analysts Covering GKOS
1 Year
1 Year Success Rate
14/14 ratings generated profit
1 Year Average Return
+72.22%
reiterated a buy rating 2 months ago
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +72.22% per trade.
---